SCHEMBL2996166

SCHEMBL2996166

COC(=O)[C@@H](N)[C@H](O)c1ccc(S(C)(=O)=O)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
TSHR P16473 1/20 0.48
MEN1 O00255 1/20 0.47
CYP3A4 P08684 1/20 0.47
KMT2A Q03164 1/20 0.47
GRM4 Q14833 1/20 0.42
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
ACHE P22303 1/20 0.40
CA14 Q9ULX7 1/20 0.40
ENPP2 Q13822 1/20 0.39
AKR1C3 P42330 2/20 0.37
AKR1C2 P52895 2/20 0.37
SLC1A3 P43003 1/20 0.37
SLC1A2 P43004 1/20 0.37
SLC1A1 P43005 1/20 0.37
EPHX2 P34913 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25588104 0.86 LMNA (0.44) LMNATSHRMEN1CYP3A4KMT2A
SCHEMBL1835877 0.85 LMNA (0.46) LMNATSHRMEN1CYP3A4KMT2A
SCHEMBL3637756 0.85 LMNA (0.46) LMNATSHRMEN1CYP3A4KMT2A
SCHEMBL5013214 0.85 LMNA (0.46) LMNATSHRMEN1CYP3A4KMT2A
SCHEMBL25588108 0.84 LMNA (0.42) LMNATSHRMEN1CYP3A4KMT2A
SCHEMBL4247092 0.82 LMNA (0.51) LMNATSHRMEN1CYP3A4KMT2A
SCHEMBL21853751 0.82 LMNA (0.51) LMNATSHRMEN1CYP3A4KMT2A
SCHEMBL21791552 0.82 LMNA (0.51) LMNATSHRMEN1CYP3A4KMT2A
SCHEMBL2065376 0.82 LMNA (0.51) LMNATSHRMEN1CYP3A4KMT2A
SCHEMBL21853762 0.82 LMNA (0.51) LMNATSHRMEN1CYP3A4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118084745-A Preparation method of florfenicol intermediate D-ester 和融(河北)药业有限公司 2024-05-28 CN disclosed
US-20230183175-A1 METHOD FOR PREPARING INTERMEDIATE FOR USE IN SYNTHESIS OF FLORFENICOL AND COMPOUNDS PREPARED THEREBY HEADING NANJING PHARMTECHNOLOGIES CO LTD (CN) 2023-06-15 US disclosed
US-20230183175-A1 METHOD FOR PREPARING INTERMEDIATE FOR USE IN SYNTHESIS OF FLORFENICOL AND COMPOUNDS PREPARED THEREBY HEADING NANJING PHARMTECHNOLOGIES CO LTD (CN) 2023-06-15 US disclosed
WO-2020135000-A1 PREPARATION METHOD FOR THREE-PHENYL-L-SERINE OR DERIVATIVES THEREOF AND ETHYL ESTER THEREOF 苏州引航生物科技有限公司 2020-07-02 WO disclosed
EP-1928820-B1 A PROCESS FOR PREPARING ESTER OXAZOLIDINE COMPOUNDS AND THEIR CONVERSION TO FLORFENICOL INTERVET INT BV (NL) 2014-01-29 EP disclosed
US-7786329-B2 Process for preparing ester oxazolidine compounds and their conversion to Florfenicol INTERVET INC. (US) 2010-08-31 US disclosed
EP-1934190-A2 AN IMPROVED PROCESS FOR PREPARING OXAZOLIDINE PROTECTED AMINODIOL COMPOUNDS USEFUL AS INTERMEDIATES TO FLORFENICOL Schering-Plough Ltd. (CH) 2008-06-25 EP disclosed
EP-1934189-A2 A PROCESS FOR PREPARING OXAZOLIDINE PROTECTED AMINODIOL COMPOUNDS USEFUL AS INTERMEDIATES TO FLORFENICOL Schering-Plough Ltd. (CH) 2008-06-25 EP disclosed
EP-1928820-A2 A PROCESS FOR PREPARING ESTER OXAZOLIDINE COMPOUNDS AND THEIR CONVERSION TO FLORFENICOL Schering-Plough Ltd. (CH) 2008-06-11 EP disclosed
WO-2007030405-A2 A PROCESS FOR PREPARING ESTER OXAZOLIDINE COMPOUNDS AND THEIR CONVERSION TO FLORFENICOL SCHERING-PLOUGH LTD. (CH) 2007-03-15 WO disclosed
WO-2007030385-A2 A PROCESS FOR PREPARING OXAZOLIDINE PROTECTED AMINODIOL COMPOUNDS USEFUL AS INTERMEDIATES TO FLORFENICOL SCHERING-PLOUGH LTD. (CH) 2007-03-15 WO disclosed
WO-2007030386-A2 AN IMPROVED PROCESS FOR PREPARING OXAZOLIDINE PROTECTED AMINODIOL COMPOUNDS USEFUL AS INTERMEDIATES TO FLORFENICOL SCHERING-PLOUGH LTD. (CH) 2007-03-15 WO disclosed
US-20070055080-A1 Process for preparing ester oxazolidine compounds and their conversion to Florfenicol SCHERING-PLOUGH ANIMAL HEALTH CORP. 2007-03-08 US disclosed
US-20070055066-A1 Process for preparing oxazolidine protected aminodiol compounds useful as intermediates to florfenicol SCHERING-PLOUGH ANIMAL HEALTH CORP 2007-03-08 US disclosed
US-20070055067-A1 Process for preparing oxazolidine protected aminodiol compounds useful as intermediates to Florfenicol SCHERING-PLOUGH ANIMAL HEALTH CORP. 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070055080-A1 Process for preparing ester oxazolidine compounds and their conversion to Florfenicol CYP4F8, CYP4F2, CYP2F1 LMNA 1934/4885TSHR 3720/4885MEN1 1509/4885
US-20070055067-A1 Process for preparing oxazolidine protected aminodiol compounds useful as intermediates to Florfenicol DHFR, DPYD, AMPD2 LMNA 1668/4885TSHR 4433/4885MEN1 1783/4885
US-20070055066-A1 Process for preparing oxazolidine protected aminodiol compounds useful as intermediates to florfenicol DHFR, DPYD, AMPD2 LMNA 1668/4885TSHR 4433/4885MEN1 1783/4885
US-20230183175-A1 METHOD FOR PREPARING INTERMEDIATE FOR USE IN SYNTHESIS OF FLORFENICOL AND COMPOUNDS PREPARED THEREBY CYP4F2, CYP4F3, CYP2F1 LMNA 3718/4885TSHR 4697/4885MEN1 1428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.